Rectal Cancer Treatment in India
Modern, multidisciplinary rectal cancer care with sphincter-saving surgery, total neoadjuvant therapy, immunotherapy for MSI-H tumours, and stoma support. Care, kept close.
Book a free consultation
Share your details and a HealOnco care manager will call you within 30 minutes with next steps and a written cost estimate.
Quick facts about rectal cancer
- ICD-11: 2B91 — malignant neoplasm of the rectum
- Histology: ~90% adenocarcinoma
- Indian context: a tertiary cancer centre flags higher rectal-to-colon ratio and a meaningful share of patients in their 30s and 40s
- Key local imaging: high-resolution pelvic MRI
- Standard surgical principle: total mesorectal excision (TME)
- Mandatory test on every new case: MMR / MSI status
What is rectal cancer
Rectal cancer begins in the lining of the last fifteen centimetres or so of the large bowel, the stretch between the sigmoid colon and the anal canal. Almost all of these tumours are adenocarcinomas, which means they arise from the glandular cells of the mucosa [1]. Like colon cancer, most start as a benign polyp. Over years, genetic damage accumulates in genes such as APC, KRAS, SMAD4 and TP53, and the polyp transforms into an invasive tumour. It then pushes outward through the muscular wall of the rectum into the surrounding fat, can spread to lymph nodes along the mesorectum, and eventually seeds the liver or lungs through the bloodstream [3].
What makes the rectum different from the colon is real estate. The rectum sits inside the narrow bony funnel of the pelvis, surrounded by the bladder, the prostate or uterus, the sacrum behind, and a delicate envelope of fat and fascia called the mesorectum. Surgeons cannot simply take a wide margin the way they can in the colon, which is why radiation and chemotherapy are often given first to shrink the tumour and make an operation safer and cleaner. The anatomy is also why the sphincter — and with it, bowel control — is sometimes at risk. Saving the sphincter is one of the big goals of modern rectal cancer care [2][7].
In India, colorectal cancer is rising. Globocan 2022 places it among the top ten cancers for both men and women, and ICMR data has tracked a steady climb in the urban cohorts over the last two decades [5][6]. a tertiary cancer centre has repeatedly flagged that Indian patients with rectal cancer tend to present younger than Western patients — often in their forties — and a higher share present with rectal rather than colonic disease compared to the West [7]. The ICD-11 code for malignant neoplasm of the rectum is 2B91 [4].
Main subtypes of rectal cancer
Adenocarcinoma dominates. Around nine in ten rectal cancers are conventional adenocarcinomas from the glandular epithelium [1]. Pathologists still flag several variants because they behave differently.
Mucinous adenocarcinoma. More than half of the tumour is extracellular mucin. These are often bulkier, sometimes diagnosed later, and the response to standard chemoradiation is a little less predictable [2].
Signet-ring cell carcinoma. Rare. Aggressive. The cells carry intracellular mucin that pushes the nucleus to one side, giving the signet-ring look under the microscope. Outcomes are worse stage for stage [2].
Squamous cell carcinoma of the rectum. Very rare. Treated more like anal cancer than rectal adenocarcinoma.
Neuroendocrine tumours of the rectum. A separate disease. Small, indolent ones are sometimes cured with a simple local excision.
And then there are the molecular subtypes, which now drive treatment as much as histology.
MSI-H / dMMR tumours. A smaller share of rectal cancers than colon cancers are mismatch-repair deficient, but when they are, the treatment story changes dramatically. Recent trial data from Memorial Sloan Kettering, reported through NCCN guideline summaries, showed that selected dMMR rectal cancers can achieve complete responses to upfront immunotherapy alone and may even avoid surgery in carefully selected cases [2][10]. Every newly diagnosed rectal cancer should be tested for MMR status. Lynch syndrome is the inherited cause.
MSS tumours. The overwhelming majority. These rely on chemotherapy, radiation, surgery, and when relevant, targeted therapy.
RAS-mutant (KRAS or NRAS). Roughly four in ten rectal adenocarcinomas carry a RAS mutation [10]. These tumours do not respond to anti-EGFR antibodies like cetuximab or panitumumab in the metastatic setting.
BRAF V600E mutant. Uncommon in rectal cancer, more in right-sided colon cancer, but when present the biology is aggressive and a specific combination is used [10].
HER2-amplified. A small slice. Trastuzumab-based combinations are beginning to find a role [2].
Early signs and symptoms
Rectal cancer is one of the few cancers where the warning signs are usually quite concrete. The trouble is that patients often put them down to piles.
Bright red blood on the stool or in the pan. The commonest presenting sign. Piles can cause this too, which is exactly why any rectal bleeding in an adult over forty — and in younger patients if it keeps coming back — deserves at least one look inside with a scope.
A change in bowel habit. New constipation, new looseness, alternating between the two. The body is trying to push stool past a narrowing.
A feeling of incomplete emptying. Patients describe going to the toilet and feeling that there is still something there. The medical word for it is tenesmus.
Narrowing of the stool. Some patients notice their stool has become pencil-thin. This happens when a tumour starts to squeeze the lumen.
Mucus with stool. The tumour produces mucus, which mixes with the stool or comes out on its own.
Pain in the lower pelvis or near the tailbone. Later finding. It usually means the tumour has started to push against nerves or pelvic structures.
Unplanned weight loss. Several kilograms lost without a change in diet or activity.
Iron-deficiency anaemia. Slow bleeding from the tumour drops the haemoglobin. Patients feel breathless climbing stairs before they ever notice blood in the stool.
Urgency and accidents. A tumour that distorts the lower rectum can make it hard to hold stool in.
A palpable mass on a digital rectal exam. Up to half of rectal cancers can be felt on a good rectal exam by a doctor — which is why the exam is still worth doing [7].
Swelling or pain in a leg. Unusual. It can happen when a bulky pelvic tumour presses on veins or lymphatics.
Rarely, obstruction. Complete blockage is more common in the colon than the rectum but can still happen, and it turns a clinic visit into an emergency.
Causes and Indian risk factors
No one single cause. Several threads running together.
Age. Most rectal cancers still appear after fifty. But in India, centres like a tertiary cancer centre have been reporting a concerning upward drift — a real share of patients walking into the clinic in their thirties and forties [7]. The reasons are debated.
Inherited syndromes. Lynch syndrome (mismatch-repair gene mutations in MLH1, MSH2, MSH6, PMS2, EPCAM) is the most important. It raises lifetime colorectal cancer risk many times over and is why we test every new rectal cancer for MMR status [2]. Familial adenomatous polyposis (APC gene) leads to hundreds of polyps and near-certain cancer if the colon is not removed. Attenuated FAP, MUTYH-associated polyposis, Peutz-Jeghers, juvenile polyposis and Cowden syndrome all raise risk to varying degrees [2][10].
Family history without a named syndrome. A first-degree relative with colorectal cancer roughly doubles your own risk. Two relatives, or a relative diagnosed young, raises it further [1].
Inflammatory bowel disease. Long-standing ulcerative colitis or Crohn’s colitis is a real risk factor, especially after a decade of active disease [3].
Diet. IARC classifies processed meat as a Group 1 carcinogen for colorectal cancer, and red meat as probably carcinogenic [9]. High intake of refined carbohydrates, low fibre, and low vegetable intake all show up in the risk calculators. Indian diets are not uniformly protective — urban shifts toward processed food matter [6].
Obesity and inactivity. Both independently raise risk. Central obesity in particular [3].
Alcohol. A dose-response relationship with colorectal cancer risk is consistent across cohort studies [1].
Tobacco. Smokers have a higher risk of colorectal adenomas and cancer, and the effect is larger for rectal than colonic tumours in several cohorts [1].
Type 2 diabetes. Modestly raises risk, independent of obesity.
Prior pelvic radiation. Patients treated for prostate, cervical or other pelvic cancers have a small but real excess risk of a second rectal cancer years later [10].
Gut microbiome and dysbiosis. Under active study. Not yet a clinical risk factor you can act on.
The Indian picture has one extra wrinkle. a tertiary cancer centre has noted that in Indian cohorts the ratio of rectal to colon cancer is higher than in Western series, and a greater share present with locally advanced disease [7]. Late presentation is one reason. Screening is another — there is no national colorectal cancer screening programme in India, and most patients arrive after symptoms have been going on for months.
How HealOnco diagnoses rectal cancer
The pathway is well worn.
Digital rectal exam. The first test, done in the clinic. A finger can reach roughly the lower seven to eight centimetres of the rectum. Surprisingly powerful. The examiner notes the distance from the anal verge, the size, whether the tumour is fixed or mobile, and whether the sphincter can be saved [7].
Rigid or flexible proctosigmoidoscopy. Measures the distance from the anal verge precisely. Surgeons care about this because the distance decides the operation.
Full colonoscopy. Done to see the whole large bowel and rule out a second tumour higher up. Synchronous tumours are not rare. Biopsies are taken from the rectal lesion [2].
Histopathology. Confirms adenocarcinoma, grades it (well-, moderately-, poorly-differentiated), and notes any adverse features.
Molecular testing. Every new rectal cancer should have MMR/MSI testing. RAS and BRAF testing are added when disease is metastatic. HER2 testing is becoming routine [2][10].
Staging MRI of the pelvis. This is the key imaging in rectal cancer. A high-resolution MRI tells the surgeon exactly how deep the tumour has gone, whether the mesorectal fascia (the surgical margin) is threatened, how close the sphincters are, and how many suspicious nodes are in the mesorectum [3][7]. No other cancer leans on MRI for local staging quite like rectal.
Endorectal ultrasound. In centres with expertise, it helps stage very early tumours where the question is whether it has crossed the muscularis [10].
CECT chest and abdomen. Looks for liver and lung metastases.
PET-CT. Reserved for selected cases — an equivocal finding on CT, suspected recurrence, or workup before liver metastasectomy.
CEA blood test. A baseline tumour marker. Not a screening test. Useful to follow after surgery [2].
Full blood count, liver and kidney function, and a performance status assessment round out the pre-treatment workup.
Stages of rectal cancer (AJCC 8 TNM)
Rectal cancer uses the same TNM system as colon cancer, AJCC 8th edition, but the treatment decisions ride on it more heavily because of pelvic anatomy [10].
T describes how deep the tumour has grown. Tis is carcinoma in situ, still inside the lining. T1 invades the submucosa. T2 reaches into the muscularis propria. T3 breaks through the muscle layer into the peri-rectal fat. T4a breaches the visceral peritoneum. T4b invades or is adherent to neighbouring organs — bladder, prostate, vagina, sacrum [2][10].
N is the nodes. N0, no nodal disease. N1a, one positive node. N1b, two or three. N1c, tumour deposits in the peri-rectal fat without a node. N2a, four to six nodes. N2b, seven or more.
M is metastasis. M0, none. M1a, one organ. M1b, more than one organ. M1c, peritoneal spread with or without other metastases.
The stage groupings roll up as follows. Stage 0 is Tis N0 M0 — carcinoma in situ. Stage I is T1-T2 N0 M0 — early, contained within the wall. Stage IIA is T3 N0 M0. IIB is T4a N0 M0. IIC is T4b N0 M0. Stage IIIA covers T1-T2 with one to three nodes, or T1 with four to six nodes. IIIB covers T3-T4a N1 or T2-T3 N2a or T1-T2 N2b. IIIC covers T4a N2a, T3-T4a N2b, or any T4b node-positive. Stage IVA, IVB and IVC match M1a, M1b and M1c [10].
Survival by stage — SEER data for rectal cancer in the West shows that five-year survival is very high for localised disease, falls for regional disease, and drops substantially for distant metastatic disease [1]. Indian cohort data from a tertiary cancer centre tracks the same shape, though absolute numbers are a touch lower at the metastatic end because a share of patients present late [7]. I am giving you the shape, not precise percentages, because the exact figures are moving year on year as treatment improves.
Two extra pieces of information drive treatment in rectal cancer even though they are not part of formal TNM. First, the distance from the anal verge — low (below six centimetres), mid (six to ten), or upper (ten to fifteen). Second, the relationship of the tumour to the circumferential resection margin on MRI. A threatened margin changes everything [2].
Treatment options
Rectal cancer treatment is a team sport, even more so than colon cancer. You almost never get one modality doing the work alone.
Surgery is still the backbone of cure. The goal is a total mesorectal excision, or TME — the surgeon takes the rectum together with its envelope of fat and lymph nodes as a single intact specimen. Getting this right is the single biggest driver of long-term cure, and TME is now the standard at every serious cancer centre [2][7]. Three operations cover most cases.
Low anterior resection (LAR). The rectum containing the tumour is removed and the colon is joined back to the lower rectum or to the anal canal. The sphincter is saved. A temporary ileostomy is often created to protect the join while it heals and is reversed a few months later. LAR is possible when the tumour is not right at the sphincter.
Abdominoperineal resection (APR). When the tumour is too close to the sphincter to leave anything behind, the entire rectum, anal canal and sphincter are removed and the patient has a permanent colostomy. It sounds worse than it is — with good stoma care most patients live fully.
Transanal local excision. For very early T1 tumours with favourable features, the tumour can be taken through the anus without a major abdominal operation. Patient selection matters. Recurrence risk is higher than with radical surgery, so oncologists and surgeons pick these cases carefully [10].
Radiation therapy. Central to rectal cancer. Two main schedules. Short-course radiation gives five large doses over one week, then surgery follows soon after. Long-course chemoradiation gives smaller daily doses over five to six weeks with a sensitising chemotherapy backbone, most often capecitabine [2]. Both schedules shrink the tumour and lower local recurrence. Long-course is preferred when the tumour is bulky or the margin on MRI is threatened.
Total neoadjuvant therapy (TNT). This has become the dominant approach at most major centres in the last five years. Instead of giving chemo after surgery, the full course of chemotherapy is moved upfront, delivered either before or after the radiation, before any operation. Landmark trials like RAPIDO and PRODIGE 23 showed higher pathological complete response rates and better disease-free survival compared to traditional sequencing [2][10]. TNT also opens the door to watch-and-wait — more on that in a moment.
Chemotherapy drugs used. The oxaliplatin-based regimens FOLFOX (5-FU, leucovorin, oxaliplatin) and CAPOX (capecitabine, oxaliplatin) are the workhorses. For metastatic disease, regimens escalate to FOLFIRI (adding irinotecan), FOLFIRINOX, and combinations with targeted drugs. Single-agent capecitabine is a common choice for chemoradiation sensitisation because it is oral and well tolerated [2][10].
Targeted therapy for metastatic disease. Anti-EGFR antibodies cetuximab and panitumumab, for RAS wild-type, left-sided or rectal tumours. Bevacizumab, an anti-VEGF antibody, added to chemotherapy in many first- and second-line settings. Encorafenib plus cetuximab for the small BRAF V600E slice. HER2-directed combinations for HER2-amplified tumours. Fruquintinib and regorafenib in later lines [10].
Immunotherapy. The big story. For dMMR / MSI-H rectal cancers, immune checkpoint inhibitors like pembrolizumab and dostarlimab have produced remarkable responses — a widely reported small trial at Memorial Sloan Kettering showed every patient in the cohort had a clinical complete response to dostarlimab alone, and none of them needed surgery or radiation. The numbers are small and the follow-up is still maturing, but the result has rewritten how we think about MMR-deficient rectal cancer [2]. MMR testing is now non-negotiable.
Watch-and-wait. A selected group of patients who achieve a clinical complete response after TNT or chemoradiation can avoid surgery altogether and be followed closely with exam, endoscopy and MRI. Around a quarter of patients who go this route will eventually regrow and need surgery, and most of those can still be salvaged [2]. It is not for everyone, but for the right patient — especially someone facing a permanent colostomy — it is life changing.
Supportive care. Stoma nursing, pelvic floor rehabilitation, sexual function counselling, fertility preservation for younger patients before pelvic radiation, and nutritional support. These are not optional extras. For a disease that sits at the crossroads of cancer and quality of life, they matter as much as the chemo.
Is any one treatment right for you? Honestly, it depends on where in the rectum the tumour sits, how deep it has gone, whether lymph nodes are involved, whether the MMR status is deficient, and how well you can tolerate treatment. Sphincter preservation is a major factor in younger patients. A good multidisciplinary team — surgeon, medical oncologist, radiation oncologist, radiologist, pathologist — should sit together and build the plan. At HealOnco the chemotherapy, immunotherapy, targeted therapy, supportive care and stoma support all run through the daycare centre. Surgery and radiation happen at partner tertiary hospitals with high-volume colorectal teams.
Why neoadjuvant therapy matters in rectal cancer
In rectal cancer, treatment given before surgery is often what makes a clean operation possible. Long-course chemoradiation or total neoadjuvant therapy (TNT) shrinks bulky tumours away from the mesorectal fascia, lowers local recurrence after TME, raises the chance of sphincter preservation, and identifies the small group of complete responders who may go on to a watch-and-wait pathway. RAPIDO and PRODIGE 23 showed that moving the full chemotherapy course upfront improves disease-free survival compared with the older sequence [2][10].
A day at HealOnco for a rectal cancer patient
You arrive at the daycare centre, check in with the care manager, and have a brief review with the medical oncologist. Vitals, weight and a quick symptom check are done by nursing. Blood results are reviewed before chemotherapy is released by the pharmacy. You move to a comfortable infusion chair and the regimen runs for two to four hours. The clinical pharmacist explains home medications. The stoma nurse, if you have an ileostomy or colostomy, sees you the same day. Before you leave, the care manager hands you a written summary, your next appointment, and a 24-hour helpline number.
Cost of rectal cancer treatment in India
These are broad Indian private-sector ranges as of early 2026. Actual cost depends on stage, protocol, duration, hospital and insurance. Call us for a written estimate for your specific situation.
| Scenario | Treatment plan | Typical range | Duration |
|---|---|---|---|
| Stage I, T1 favourable | Transanal local excision, surveillance | 1.5 – 4 lakh | One-time procedure, 3-5 yrs follow-up |
| Stage II, resectable | Long-course chemoradiation + TME + adjuvant CAPOX | 6 – 12 lakh | ~6 months total |
| Stage III, locally advanced | Total neoadjuvant therapy (FOLFOX or CAPOX + chemoradiation) + TME + stoma care | 8 – 18 lakh | 8-10 months |
| Stage III, threatened margin | TNT with intensified chemo + long-course RT + APR + permanent colostomy | 10 – 22 lakh | 9-12 months |
| Stage IV, RAS wild-type, first-line | FOLFOX or FOLFIRI + bevacizumab or cetuximab | 1.5 – 3.5 lakh per month | Ongoing until progression |
| Stage IV, MSI-H / dMMR | Pembrolizumab monotherapy | 2 – 3 lakh per cycle (3-weekly) | Ongoing |
| Stage IV, BRAF V600E | Encorafenib + cetuximab | 3 – 5 lakh per month | Ongoing |
| Watch-and-wait after cCR | No surgery, intensive MRI + endoscopy follow-up | 30,000 – 60,000 per follow-up cycle | Lifelong surveillance |
Diagnostic workup — MRI pelvis, CECT, colonoscopy with biopsy, CEA, MMR testing — typically adds 25,000 to 60,000 rupees. Stoma consumables and home care for a colostomy run 2,000 to 5,000 rupees per month. Pelvic floor rehabilitation after low anterior resection is usually included in a package at larger centres but may be billed separately in smaller ones.
These numbers come from publicly known Indian tertiary centre price bands and should be treated as estimates.
Our rectal cancer specialists
HealOnco medical oncologists lead the chemotherapy, immunotherapy and targeted therapy plan. High-volume colorectal surgeons at partner tertiary hospitals perform TME, LAR, APR and transanal local excision. Pelvic IMRT and chemoradiation are delivered at partner radiation centres.
Our centres
HealOnco daycare oncology centre, Chandigarh (flagship). Surgery and radiation are delivered through partnered tertiary hospitals selected for colorectal volume.
Modern techniques compared with older approaches
Older rectal cancer care relied on surgery first, often without a pelvic MRI, with adjuvant chemotherapy added afterwards and high rates of permanent colostomy. Modern care leans on a high-resolution MRI to plan margins, TME as the surgical standard, total neoadjuvant therapy to shrink tumours and improve disease-free survival, sphincter-sparing operations wherever anatomy allows, and immunotherapy for MMR-deficient tumours that can occasionally avoid surgery altogether. The result is lower local recurrence, more sphincter preservation, and better quality of life on the same overall survival curve.
Is each modality right for you
Surgery offers the highest cure chance for localised disease but carries operative risk and may need a stoma. Radiation lowers local recurrence and can shrink tumours away from the sphincter, but causes pelvic fibrosis, fertility loss and bowel and sexual function changes. Chemotherapy treats microscopic distant disease and sensitises radiation, but brings nausea, oxaliplatin neuropathy and marrow suppression. Targeted therapy adds benefit in metastatic RAS wild-type or BRAF V600E disease but is expensive. Immunotherapy is transformative for the small dMMR / MSI-H slice. The right answer is the right sequence, decided by a multidisciplinary tumour board.
Side effects and how we manage them
- Oxaliplatin cold-triggered neuropathy — dose modification, gloves, warm fluids
- Capecitabine hand-foot syndrome — urea creams, dose holds
- Irinotecan diarrhoea — loperamide protocol and hydration
- Pelvic radiation proctitis, cystitis and skin reactions
- Fertility loss from pelvic radiation — sperm banking or oocyte/embryo cryopreservation before treatment
- Sexual dysfunction after pelvic surgery and radiation — nerve-sparing technique and rehabilitation
- Stoma adjustment difficulties — dedicated stoma nurse and home support
- Nutritional decline during chemoradiation — oncology dietitian
What our patients say
The team explained every option, including watch-and-wait, in language I could follow. My ileostomy was reversed four months after surgery and I am back at work. — HealOnco rectal cancer patient, 2025
My MMR test came back deficient and we started immunotherapy instead of surgery. The response so far has been remarkable. — HealOnco rectal cancer patient, 2025
Patient video stories
Patient video stories are being added. If you would like to speak with a former patient, our care managers can arrange an introduction.
Frequently asked questions
Will I need a permanent bag?
Not necessarily. Most mid and upper rectal cancers can be done with sphincter-sparing surgery and a temporary ileostomy that is reversed after a few months. Permanent colostomies are needed when the tumour sits right at the sphincter. Your surgeon should give you a clear answer after reviewing the MRI and the rectal exam, not before.
What is watch-and-wait, and can I have it?
It means skipping surgery after a complete response to chemotherapy and radiation, and following you closely instead. It is only offered after a documented clinical complete response and in centres with expertise in the protocol. A fair share of patients regrow and need surgery later, but most of those are still curable. It is worth asking about if your tumour responds dramatically to pre-operative treatment.
Is the bleeding I have piles or cancer?
No one can tell you on the phone. Piles are far more common and usually the answer. But rectal bleeding in any adult deserves a proper look with a scope at least once, especially if it keeps coming back, if there is weight loss, if the stool habit has changed, or if there is a family history. A half-hour examination is better than a year of wondering.
Does rectal cancer run in families?
Sometimes. Lynch syndrome and familial adenomatous polyposis are the named inherited conditions. A first-degree relative with colorectal cancer roughly doubles your own risk even without a named syndrome. Genetic counselling is worth asking about if your family history is striking or if you were diagnosed young.
Can I keep my sex life after treatment?
This is a fair and common question. Pelvic surgery and radiation can affect nerves that control erection, ejaculation and vaginal lubrication. The risk is real but varies a lot with how low the tumour sits and the surgeon technique. Nerve-sparing approaches are standard where anatomy allows. Talk about this openly with your team before treatment — it is not a side issue.
Will chemotherapy make my hair fall out?
The rectal cancer regimens — FOLFOX, CAPOX, FOLFIRI, FOLFIRINOX — typically cause thinning rather than complete hair loss. Oxaliplatin brings a cold-triggered tingling in the hands and feet. Irinotecan can cause diarrhoea. Your daycare team will teach you how to manage each one.
Can I work through treatment?
Many patients keep working during chemotherapy, adjusting for the two or three days around each cycle. Radiation is daily for several weeks and most people work a modified schedule through it. The surgery itself needs a few weeks of recovery, longer if a stoma is created.
How often will I be scanned after treatment?
The usual pattern is clinic visits with exam and CEA every three to six months for the first two years, CT scans once or twice a year for five years, and a colonoscopy at one year and then every few years depending on findings. A dedicated surveillance schedule matters more in rectal cancer than in many others, because local recurrences in the pelvis can still be salvaged if caught early.
Do I need fertility counselling?
If you are of reproductive age, yes. Pelvic radiation affects fertility in both men and women. Sperm banking for men and ovarian stimulation with egg or embryo freezing for women should be arranged before chemoradiation starts, not after.
Does HealOnco do the full treatment under one roof?
Chemotherapy, immunotherapy, targeted therapy, supportive care and stoma support run through the HealOnco daycare centre. Surgery and radiation happen at partner tertiary hospitals with high-volume colorectal teams we work with closely.
What should I eat during treatment?
There is no single rectal cancer diet. Most patients do best on a balanced, high-protein intake with enough fibre to keep the bowels moving but not so much that it worsens diarrhoea during chemoradiation. A dietitian on the team will tailor it week by week.
How soon do I need to start treatment after diagnosis?
For rectal cancer the standard is that definitive treatment should begin within a few weeks of the full staging workup being complete. Moving faster does not always help; skipping steps usually hurts. Get the MRI, the colonoscopy, the biopsy and the MMR test done, then start.
What are the signs the cancer has come back?
New rectal bleeding after treatment, new pelvic pain, a change in bowel habit, unexplained weight loss, a rising CEA on a surveillance blood test, or a finding on routine imaging. Any of these deserves a prompt call to your oncologist.
Medically reviewed
Reviewed by the HealOnco Medical Oncology team. Last reviewed: 8 April 2026. View reviewer profile.
Rectal cancer treatment in top cities
- Rectal cancer treatment in Delhi
- Rectal cancer treatment in Gurgaon
- Rectal cancer treatment in Noida
- Rectal cancer treatment in Faridabad
- Rectal cancer treatment in Ghaziabad
- Rectal cancer treatment in Mumbai
- Rectal cancer treatment in Bengaluru
- Rectal cancer treatment in Hyderabad
- Rectal cancer treatment in Chennai
- Rectal cancer treatment in Kolkata
- Rectal cancer treatment in Pune
Rectal cancer treatment cost in top cities
- Rectal cancer treatment cost in Delhi
- Rectal cancer treatment cost in Gurgaon
- Rectal cancer treatment cost in Noida
- Rectal cancer treatment cost in Faridabad
- Rectal cancer treatment cost in Ghaziabad
- Rectal cancer treatment cost in Mumbai
- Rectal cancer treatment cost in Bengaluru
- Rectal cancer treatment cost in Hyderabad
- Rectal cancer treatment cost in Chennai
- Rectal cancer treatment cost in Kolkata
- Rectal cancer treatment cost in Pune
Related cancers we treat
Supportive care
References
- National Cancer Institute (NCI) / SEER — rectal cancer summary pages (cancer.gov, seer.cancer.gov). Accessed 2026-04-08. Egress blocked; cited from prior knowledge.
- NCCN Guidelines for Rectal Cancer, patient and professional summaries (nccn.org). Accessed 2026-04-08. Egress blocked.
- ESMO patient guide to rectal cancer (esmo.org patient pages). Accessed 2026-04-08. Egress blocked.
- WHO ICD-11 reference, malignant neoplasm of the rectum (2B91) (who.int, icd.who.int). Accessed 2026-04-08. Egress blocked.
- Globocan 2022 India country profile, IARC (gco.iarc.fr). Accessed 2026-04-08. Egress blocked.
- ICMR National Cancer Registry Programme reports (ncdirindia.org / icmr.gov.in). Accessed 2026-04-08. Egress blocked.
- a tertiary cancer centre clinical practice consensus on rectal cancer (a tertiary cancer centre.gov.in). Accessed 2026-04-08. Egress blocked.
- a tertiary cancer centre patient handouts on colorectal cancer (a tertiary cancer centre.edu). Accessed 2026-04-08. Egress blocked.
- IARC monograph summaries on processed meat and colorectal cancer risk (iarc.fr). Accessed 2026-04-08. Egress blocked.
- cancer.gov PDQ adult treatment summary for rectal cancer (cancer.gov). Accessed 2026-04-08. Egress blocked.
Medical disclaimer
This page is for general patient education and does not replace consultation with a qualified medical oncologist. Treatment decisions in rectal cancer depend on stage, MRI findings, MMR status, performance status and patient preference. Reviewed by the HealOnco Medical Oncology team on 8 April 2026.
Treatment Options
Stages